Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. develops clinical-stage cancer immunotherapies based on antibody engineering and target identification. Company news commonly covers its next-generation antibody therapeutics portfolio, including IPH4502, a Nectin-4 antibody-drug conjugate for solid tumors; lacutamab, an anti-KIR3DL2 antibody for cutaneous and peripheral T-cell lymphomas; monalizumab, an anti-NKG2A antibody developed with AstraZeneca for non-small cell lung cancer; and IPH5201, an anti-CD39 antibody studied in non-small cell lung cancer.
Updates also address collaborations with biopharmaceutical partners such as Sanofi and AstraZeneca, oncology conference presentations, business updates, annual meeting matters, share-count and voting-right disclosures, and annual reporting under French and U.S. public-company requirements.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) will host a conference call and live webcast on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. The call will feature CEO Jonathan Dickinson, COO Yannis Morel, CFO Frédéric Lombard and VP Investor Relations & Communications Stéphanie Cornen.
The live webcast can be accessed via Q4 links provided by the company and through the Investors section of Innate Pharma’s website, where a replay will also be available. Innate Pharma is a clinical-stage biotechnology company focused on immuno-oncology and antibody-drug conjugates, including its lead Nectin-4 ADC IPH4502 and partnered late-stage assets lacutamab with Sobi and monalizumab with AstraZeneca.
Innate Pharma (Euronext Paris: IPH, Nasdaq: IPHA) plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T‑cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome. This advancement is subject to closing of its strategic partnership with Sobi, including required anti‑trust clearance.
According to Innate, the agreement’s USD 75 million upfront payment, payable at closing, and near‑term milestones tied to Sézary syndrome are expected to fund TELLOMAK-3 execution and regulatory filings and extend the company’s cash runway through Q3 2027. Innate also appointed Markus Jensen as Chief Medical Officer and Executive Leadership Team member, effective September 1, 2026, succeeding Sonia Quaratino. Lacutamab holds multiple U.S. and EU regulatory designations and is progressing toward an open‑label, multicenter, randomized Phase 3 trial in Sézary syndrome and mycosis fungoides.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) entered a strategic partnership with Sobi to advance lacutamab in cutaneous T‑cell lymphoma (CTCL), enabling initiation of the confirmatory TELLOMAK‑3 Phase 3 study. The trial is designed to support a planned accelerated approval filing in Sézary syndrome and later full approvals in Sézary syndrome and mycosis fungoides.
According to Innate Pharma, Sobi will pay USD 75 million at closing and Innate may receive up to USD 40 million in near‑term Sézary‑linked milestones and up to USD 465 million tied to Sobi’s option for full development rights and future regulatory and commercial milestones, plus tiered double‑digit royalties on net sales. Sobi will receive exclusive global commercialization rights upon potential accelerated approval and may assume full global development rights following positive Phase 3 results, subject to closing conditions including antitrust clearance.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced that EVP Chief Medical Officer Sonia Quaratino will join the bladder cancer panel “Changing Treatment Landscape in Bladder Cancer” at the BTIG Virtual Biotechnology Conference 2026 on July 28, 2026, at 10:30 a.m. EDT / 4:30 p.m. CEST.
Innate Pharma is a clinical-stage biotechnology company developing next-generation antibody-based immunotherapies, including IPH4502 (Nectin4 ADC in solid tumors), lacutamab (anti-KIR3DL2 in cutaneous T cell lymphomas) and monalizumab (anti-NKG2A in NSCLC, in collaboration with AstraZeneca). The company collaborates with partners such as Sanofi and AstraZeneca and is headquartered in Marseille, France.
Innate Pharma (Euronext: IPH, Nasdaq: IPHA) has completed enrollment in the dose-escalation part of its Phase 1 IPH4502-101 study (NCT06781983), evaluating IPH4502, a proprietary Nectin-4 exatecan antibody-drug conjugate (ADC), in patients with advanced solid tumors known to express Nectin-4.
The open-label, multi-center trial has recruited 76 patients in France and the United States. According to Innate Pharma, IPH4502 has shown a favorable safety profile to date, with limited hematological toxicity, consistent with the company’s hypothesis that its proprietary stable linker enables slow release of free exatecan. Preliminary anti-tumor activity has been observed, including objective responses in heavily pre-treated urothelial carcinoma patients previously treated with enfortumab vedotin, as well as in non-small cell lung cancer and head and neck squamous cell carcinoma. A preliminary data readout from the 76-patient dose-escalation cohort is expected by year-end to guide dose optimization and selection of tumor types for further development.
Innate Pharma (Nasdaq: IPHA) reported the voting results of its 2026 Annual General Meeting held on May 21, 2026, in Marseille.
According to Innate Pharma, shareholders cast 94 votes out of 34,872,293 shares representing 34,921,313 voting rights, for a stated quorum of 37,136%. AGM documentation and the meeting recording will be available on the company’s website.
Innate Pharma (Nasdaq:IPHA), a clinical-stage biotech focused on cancer immunotherapies, announced that its executive team will attend the Jefferies Global Healthcare Conference 2026.
Management will hold one-on-one investor meetings in New York from June 2–4, 2026, offering updates on the company and its pipeline.
Innate Pharma (Nasdaq: IPHA) reported Q1 2026 revenue of €2.6 million, up from €1.2 million a year earlier. Cash and financial assets were €25.4 million with an expected runway until end of Q3 2026, and financial liabilities of €20.3 million.
Key R&D updates include the planned H2 2026 start of the lacutamab TELLOMAK-3 Phase 3 CTCL trial, pending non‑dilutive financing, IPH4502 Phase 1 enrollment nearing completion with preliminary anti‑tumor activity, PACIFIC‑9 Phase 3 fully enrolled with an H2 2026 data readout, and encouraging MATISSE Phase 2 pCR data for IPH5201 in NSCLC. The company completed a redundancy plan with layoffs, while Sanofi deprioritized the partnered IPH6401/SAR’514 program; $75 million remains available under the ATM facility.
Innate Pharma (IPHA) reported its capital and voting structure as of April 16, 2026. The company has 93,934,210 shares outstanding, including 93,921,863 ordinary shares, 4,766 Preferred Shares 2016, and 7,581 Preferred Shares 2017.
There are 93,921,863 theoretical voting rights and 93,903,288 exercisable voting rights, with treasury shares excluded from net voting rights, in line with AMF regulations.
Innate Pharma (Nasdaq: IPHA) will hold a conference call and webcast on May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT to provide a Q1 2026 business update. Management participants include CEO Jonathan Dickinson and CFO Frédéric Lombard.
The live webcast link and telephone registration are on the company website; a replay will be available for 90 days following the event.